THE EFFECT OF BEVACIZUMAB ON ALPHA SMOOTH MUSCLE ACTINEXPRESSION AND FIBROBLAST COUNT TO PREVENT POSTTRABECULECTOMY FIBROSIS IN NEW ZEALAND WHITE RABBIT
DOI:
https://doi.org/10.61841/60tpr326Keywords:
bevacizumab, fibrosis, glaucoma, post trabeculectomyAbstract
Background: The wound healing process is the most common cause of glaucoma surgery failure that causes the incapability of controlling the intraocular pressure (IOP) and progressive optic nerve damage.
Objective: This study aimed to analyze the effect of Bevacizumab on myofibroblast and fibroblast in the trabeculectomy area of rabbit models in order to find a safer wound healing modulator to improve surgical outcomes.
Method: Sixteen New Zealand white rabbits aged 4-6 months and weighing between 2.5 and 3.5 kg underwent trabeculectomy on the right eye with a postoperative subconjunctival injection of BSS and Bevacizumab. Subjects were put into a control and bevacizumab groups. Examinations were done, and subjects were terminated and performed enucleation on postoperative day 14. Samples were histologically stained with hematoxyline-eosin to count the fibroblast.
Result: Mann Whitney u test and independent t-test were used to analyse the data. We found both less expression of alpha smooth muscle act and a lower fibroblast count in the bevacizumab group compared to the control group, which indicates less myofibroblast, fibroblast, and scarring potential in the trabeculectomy area. There is a significant decrease in expression of α-SMA in the bevacizumab group compared to the control group (p = 0.0195), and with an independent t-test, we found less fibroblast in the bevacizumab group significantly (p = 0.0005).
Conclusion: Bevacizumab inhibits fibroblast proliferation and its differentiation to myofibroblast, which leads to less collagen production and fibrosis.
Downloads
References
[1] Breusegem, C. et al. (2010), ‘Preoperative nonsteroidal antiinflammatory drug or steroid and outcomes after trabeculectomy: a randomized controlled trial’, Ophthamology, 117, pp. 1324–1330.
[2] Gordon, M. et al. (2003), ‘The ocular hypertension treatment study: baseline factors that predict the onset of primary open-angle glaucoma’, Arch Ophthalmol., 120(4), pp. 16-7.
[3] Leung, E., Medeiros, F., and Weinreb, R. (2008), ‘Prevalence of ocular surface disease in glaucoma patients’, J Glaucoma, 17, pp. 350–355.
[4] Li, Z. et al. (2009), ‘Inhibition of vascular endothelial growth factor reduces scar formation after glaucoma filtration surgery’, Invest Ophthalmol Vis Sci, 50, pp. 5217–5225.
[5] Memarzadeh, F. et al. (2011), ‘Postoperative Use of Bevacizumab as an Antifibrotic Agent in Glaucoma Filtration Surgery in the Rabbit’, Invest Ophthalmol Vis Sci, 50, pp. 3233–3237.
[6] O’Neill, E. et al. (2010), ‘Antifibrotic activity of bevacizumab on human Tenon’s fibroblasts in vitro’, Invest Ophthalmol Vis Sci, 51, pp. 6524–6532.
[7] Overby, D., Stamer, W., and Johnson, M. (2009), ‘The changing paradigm of outflow resistance generation: towards synergistic models of the JCT and inner wall endothelium’, Exp Eye Res, 88(4), pp. 656–70.
[8] Ozgonul, C., Mumcuoglu, T., and Gunal, A. (2014), ‘The Effect of Bevacizumab on Wound Healing Modulation in an Experimental Trabeculectomy Model’, Current Eye Research, 39(5), pp. 451–459.
[9] Park, H., Kim, J., and Park, C. (2013), ‘VEGF induces TGF-beta1 expression and myofibroblast transformation after glaucoma surgery’, Am J Pathol, 182, pp. 2147–2154.
[10] Quigley, H., and Boman, A. (2006), ‘The number of people with glaucoma worldwide in 2010 and 2020’, Br J Ophthalmol, 90(3), pp. 262–7.
[11] Stamer, W., and Acott, T. (2012), ‘Current understanding of conventional outflow dysfunction in glaucoma’, Curr Opin Ophthalmol, 23(2), pp. 135–43.
[12] Sudiro, D. (2017). Effect of Triamcinolone Acetonide on TGF-β Expression Post-Trabeculectomy (Experimental Study on Oryctolagus Cuniculus). Faculty of Medicine/Dr. Soetomo General Hospital Surabaya.
[13] Zada, M., Pattamatta, U., and White, A. (2017), ‘Modulation of Fibroblasts in Conjunctival Wound Healing’, Ophthalmology, 12, pp. 1–14.
Downloads
Published
Issue
Section
License
Copyright (c) 2020 AUTHOR
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
